Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy

Arthritis Care and Research

Volumn 62, Issue 5, 2010, Pages 704-711

  Stine, Jonathan G ^a   Khokhar, Omar S ^a   Charalambopoulos, John ^a   Shanmugam, Victoria K ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTECAVIR; ETANERCEPT; HEPATITIS B VACCINE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TELBIVUDINE; UNCLASSIFIED DRUG; VIRIAD;

ANKYLOSING SPONDYLITIS; ARTICLE; AWARENESS; CONSENSUS; DISEASE EXACERBATION; DRUG MANUFACTURE; DRUG PACKAGING; EDUCATION; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; PATIENT CARE; PATIENT REFERRAL; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; PROPHYLAXIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCREENING; UNITED STATES; VIRUS REACTIVATION;

ADULT; ANTIRHEUMATIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; CLINICAL COMPETENCE; CROSS-SECTIONAL STUDIES; GUIDELINE ADHERENCE; HEPATITIS B; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOMODULATION; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RHEUMATIC DISEASES; RHEUMATOLOGY; TIME FACTORS; VIRUS ACTIVATION;

EID: 77951725797     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20209     Document Type: Article

References (42)

1. Lubel J, Testro A, Angus P. Hepatitis B reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007;37:705-712 (Pubitemid 47481164)
2. Iannitto E, Minardi V, Calvaruso G, Ammatuna E, Florena AM, Mule A, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74:254-258 (Pubitemid 40278496)
3. Yang CH, Wu TS, Chicu CT. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007;3:587-590
4. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab [letter]. N Engl J Med 2001;344:68-69 (Pubitemid 32064857)
5. Tsai FC, Hsieh SC, Chen DS, Sheu JC, Chen CH. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci 2006;51:1627-1632 (Pubitemid 44379307)
6. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001;44:339-342 (Pubitemid 32207027)
7. Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy [letter]. J Rheumatol 1998;25:2037-2038 (Pubitemid 28459328)
8. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for adult onset Still's disease. J Rheumatol 2003;30:1624-1625 (Pubitemid 36835467)
9. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-109 (Pubitemid 38067531)
10. Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of lowdose methotrexate therapy for rheumatoid arthritis [review]. Clin Exp Rheumatol 2004;22:375-376 (Pubitemid 38585245)
11. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934 (Pubitemid 41103605)
12. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-449 (Pubitemid 12139868)
13. Lok A, Lai C. Acute exacerbations in Chinese patients with chronic hepatitis: incidence, predisposing factors and etiology. J Hepatol 1990;10:29-34. (Pubitemid 20006985)
14. Khokhar OS, Farhadi A, McGrail L, Lewis JH. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 2009;55:69-75.
15. Thong B, Koh ET, Chng HH, Chow WC. Outcomes of chronic hepatitis B infection in oriental patients with rheumatic diseases. Ann Acad Med Singapore 2007;36:100-105 (Pubitemid 46640260)
16. Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007;19:619-625 (Pubitemid 47530884)
17. Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388-395 (Pubitemid 44056248)
18. Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000;18:363-368
19. Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990;112:381-382 (Pubitemid 20083615)
20. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection. Ann Rheum Dis 2004;63:ii18-24.
21. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate [letter]. Ann Rheum Dis 2003;62:686-687 (Pubitemid 36760576)
22. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy [letter]. Ann Rheum Dis 2005;64:788-789 (Pubitemid 40559316)
23. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528 (Pubitemid 351665421)
24. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B (HBV) virus reactivation with immunosuppressive therapy in rheumatic diseases: assessment and prevention strategies. Ann Rheum Dis 2006;65:983-989 (Pubitemid 44133258)
25. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784
26. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20.
27. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002;185:713-719
28. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539
29. Cacoub P, Saadoun D, Bourliere M, Khiri H, Martineau A, Benhamou Y, et al. Hepatitis B virus genotypes and extrahepatic manifestations. Hepatology 2005;43:764-770 (Pubitemid 41417733)
30. Cesur S, Akin K, Albayrak F, Birengel S, Kurt H, Balik I. Prevalence of extrahepatic illnesses in patients with chronic hepatitis b and hepatitis c: retrospective study of 435 patients. Mikrobiyol Bul 2003;37:187-93. In Turkish. (Pubitemid 37128294)
31. Guennoc X, Narbonne V, Jousse-Joulin S, Devauchelle-Pensec V, Dougados M, Daures JP, et al. Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? The ESPOIR cohort study. J Rheumatol 2009;36:1407-1413
32. Kohrt H, Ouyang D, Keeffe E. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B infection. Clin Liver Dis 2007;11:965-991 (Pubitemid 350019026)
33. Kim JS, Hahn JS, Park SY, Kim Y, Park IH, Lee CK, et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Med J 2007;48:78-89. (Pubitemid 46403637)
34. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514
35. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455
36. Charbel H, Lewis JH. Hepatitis B reactivation during chemotherapy and other immunosuppresion. In: Shetty K, Wu G, editors. Chronic viral hepatitis. 2nd ed. Totowa (NJ): Humana Press; 2009.
37. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341
38. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751 (Pubitemid 44958517)
39. Sheehan KB. E-mail survey response rates: a review. Journal of Computer-Mediated Communication 2001. URL: http://jcmc.indiana.edu/vol6/issue2/ sheehan.html.
40. Keeter S, Kohut A, Miller A, Groves R, Presser S. Consequences of non-response in a large national telephone survey. Publ Opin Q 2000;64:125-148
41. Han SH. Extrahepatic manifestations of chronic hepatitis B [review]. Clin Liv Dis 2004;8:403-418 (Pubitemid 38748611)
42. Aprosina ZG, Serov VV, Krel' PE, Ignatova TM. Extrahepatic manifestations of chronic viral liver disease [review]. Arkh Patol 1999;61:51-5. In Russian.